BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with the U.S. Food and Drug Administration (FDA). The novel drop-free therapy is poised to revolutionize the treatment of ocular Graft-versus-Host Disease (oGvHD). This key regulatory milestone, achieved following a highly productive Type C meeting, sets the stage for Signal12's transformative Phase 3 clinical research in an area of high unmet medical need. Ocular Graft-versus-Host Disease, an orphan condition impacting roughly 50,000 patients annually in the United...